Device Trial Radar · NCT05421130
Clinical Investigation of Clinical Safety and Performance of the SP-GRIPFLOW, Selective Cerebral Perfusion Catheter When Used for Cerebral Perfusion During Aortic Arch Repair
Last checked: Nov 20, 2026Latest source record: Jul 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
149
Planned (sponsor's estimate)
Start
May 2, 2022
Primary completion
Jul 1, 2023
Study completion Feb 1, 2024
Sponsor
- Lead sponsor
- Fuji Systems CorporationNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Avania
- First posted
- Jun 16, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if the SP-GRIPFLOW catheter (the catheter designed by Fuji Systems) is safe and how well it functions. The information from this research will be used to help decide if the device should be approved for sale in the European Union. The SP-GRIPFLOW catheter may not yet be used by investigators outside of the study. Through the study, FUJI will prove that the target flow as measured by the flow through the catheter(s)(cumulative flow for multiple catheters) was confirmed in 95% of cases.
Conditions
- Aortic Aneurysm
- Aortic Dissection
- Aortic Arch Aneurysm
- Aortic Arch; Aneurysm, Dissecting
Interventions
Selective Cerebral Perfusion CatheterDevice
This product is intended to be placed in the branches of the aortic arch for the cerebral perfusion during surgery of aorta.
Primary outcomes
What the sponsor says the trial is designed to measure.
- "Successful perfusion" defined by flow rate through the catheter (mL/kg/min)Time frame: The enrolment period is expected to take approximately 15 months. The duration of the subject's participation is circa 1 month. The total expected duration of the clinical investigation is, therefore, approximately 16 months.
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Universitätsklinikum Freiburg
Freiburg im Breisgau, Campus Freiburg: Hugstetter Straße 55, Germany
Universitätsklinikum Frankfurt
Frankfurt, Theodor-Stern-Kai 7,, Germany
Herzzentrum Leipzig GmbH
Leipzig, Universitätsklinik Für Herzchirurgie Strümpellstraße 39, Germany
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.